Islatravir plus ulonivirine shows promise for weekly oral HIV treatment
The untapped potential of CD8 cells
New antiretrovirals in the pipeline could be part of twice-yearly HIV treatment
Doravirine/islatravir non-inferior to Biktarvy as first-line treatment
Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens
Antibody from Tanzanian woman suppresses almost all tested HIV variants including resistant viruses in pre-clinical study
Broadly neutralising antibodies plus immune modulator may delay HIV rebound
New long-acting HIV drugs show promising early results
Broadly neutralising antibody N6LS could be part of long-acting HIV treatment
